{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-026339","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2023-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.915369+00:00","generated_at":"2026-06-12T17:40:31.675099+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Esperion Q2 U.S. product revenue +49% to $20.3M; net loss narrows to $49.9M","bullets":["Total revenue $25.8M (+37% YoY); U.S. net product revenue $20.3M (+49% YoY) driven by 26% retail Rx growth.","Net loss $49.9M ($0.46 per share) versus $66.3M ($1.05) in Q2 2022; R&D expenses fell 32% to $22.1M.","Submitted FDA sNDAs and EMA application to expand NEXLETOL/NEXLIZET labels; approvals expected 1H 2024.","Presented CLEAR Outcomes primary prevention analysis at ADA, published in JAMA, expanding addressable U.S. market to 70M patients.","Cash and investments $138.5M as of June 30, 2023; full-year 2023 opex outlook reaffirmed at $225-245M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-026339","json":"https://secwatch.observer/filing/0001628280-23-026339.json","markdown":"https://secwatch.observer/filing/0001628280-23-026339.md","text":"https://secwatch.observer/filing/0001628280-23-026339.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828023026339/0001628280-23-026339-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828023026339/espr-20230801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T17:40:31.675099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51d4d38e4e48e77625398029bc103d65303aaf89","claim":"Esperion Therapeutics, Inc. reported second quarter ended June 30, 2023 results: revenue $25.8 million, net income $49.9 million, EPS $0.46.","evidence_excerpt":"Outcomes Analysis by Glycaemic Status, presented by Kausik K Ray. Second Quarter and YTD 2023 Financial Results Total revenue for the second quarter ended June 30, 2023, was $25.8 million and $50.1 million for the six months ended June 30, 2023, compared to $18.8 million and $37.7 million for the comparable periods in 2022, an increase of 37% and 33%,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828023026339/0001628280-23-026339-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$25.8 million"},{"label":"Net income","value":"$49.9 million"},{"label":"EPS","value":"$0.46"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}